Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

CSNK2A3 (Q8NEV1) - Overview - Molecular Target Synopsis

Protein


CSNK2A3, Casein kinase II subunit alpha 3
Enzyme Classification 2.7.11.1
UniProt Q8NEV1

Also Known as CSK23_HUMAN, CSNK2A3, CSNK2A1P

Probable catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Amplification-dependent oncogene; promotes cell proliferation and tumorigenesis by down-regulating expression of the tumor suppressor protein, PML. May play a role in the pathogenesis of the lung cancer development and progression. Heterotetramer composed of two catalytic subunits (alpha chain and/or alpha' chain) and two regulatory subunits (beta chains) (By similarity). Interacts with PML.

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
399ENSG00000254598ENST00000528848ENSP00000473553
391Q8NEV1-1

Sub-cellular localization


GO terms: CSNK2A3 is active in the following subcellular-locations: nucleoplasm.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project CSNK2A3 has gain in 1 cell-lines, loss in 2 cell-lines and no signal in 1002 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are:

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: WSU-FSCCL, HCC38, TK

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: NHLF, HSMM, HMEC

(see details)

3D Structures


At greater than 90% identity similarity to CSNK2A3 there are:
149 structures (232 chains) solved
130 are solved in complex with at least one small molecule ligand
1 are solved with an approved drug

CSNK2A3 is solved in complex with the approved drug(s):

NIO/NIACIN (3WAR_A).

(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


CSNK2A3 has been screened with compounds ( bioactivities). (see details)